MPI Colloquia Series: Prof. Dr. Peter H. Seeberger, Preventing and Fighting Infectious Diseases: Carbohydrate Vaccines and Flow Chemistry

9823 1506412720

MPI Kolloquiumsreihe: Prof. Dr. Peter H. Seeberger, Preventing and Fighting Infectious Diseases: Carbohydrate Vaccines and Flow Chemistry

  • Datum: 12.10.2017
  • Uhrzeit: 16:00 - 17:00
  • Vortragender: Prof. Dr. Peter H. Seeberger
  • Direktor am Max-Planck-Institut für Kolloid- und Grenzflächenforschung, Potsdam-Golm
  • Ort: Max-Planck-Institut Magdeburg
  • Raum: Großer Seminarraum "Prigogine"

Das Max-Planck-Institut Magdeburg lädt Sie herzlich zu seiner öffentlichen Kolloquiumsreihe ein.

Hochrangige Wissenschaftler aus verschiedenen Fachgebieten, eingeladen vom Max-Planck-Institut Magdeburg, präsentieren ihre Forschungsarbeit.

Abstract

Most pathogens including bacteria, fungi, viruses and protozoa carry unique glycans on their surface. Currently, several vaccines against bacteria are marketed very successfully. Since many pathogens cannot be cultured and the isolation of pure oligosaccharides is extremely difficult, synthetic oligosaccharide antigens provide now a viable alternative. The automated synthesis platform,1, 2 has been commercialized.3,4 The quality control of synthetic oligosaccharides by ion mobility mass spectrometry (IM-MS) is fast and extremely sensitive.5 Currently, the laboratory is pursuing the development of several semi- and fully synthetic carbohydrate vaccines against severe bacterial infections, including multi-resistant hospital acquired infections.5,6 In addition to their function as antigens, synthetic oligosaccharides serve as tools to create monoclonal antibodies, and to establish glycan microarrays to map vaccine epitopes.7 Diagnostic and preventive approaches against a host of bacteria, fungi, and parasites are being pursued.

In recent years continuous flow systems have become increasingly interesting to practitioners of synthetic chemistry. Described is the use of continuous flow systems to produce drug substances and other chemicals via multi step reactions including continuous purification.8 The anti-malaria drug artemisinin and its derivatives as well as other life-saving drugs are used as examples. 8-10


1. Plante, O.J.; Palmacci, E.R.; Seeberger, P.H.; Science 2001, 291, 1523.

2. Seeberger, P.H.; Acc. Chem. Res. 2015, 48, 1450.

3. Hahm, H.S.; Schlegel, M.K.; Hurevich, M.; ….. Seeberger, P.H.; Proc Nat Acad Sci USA, 2017, online; www.glycouniverse.de

4. Hofmann, J.; Hahm, H.S.; Seeberger, P.H.; Pagel, K.; Nature 2015, 526, 241.

5. Parameswarappa, S.G.; Reppe, K.; Geissner, A.; Seeberger, P.H.; Cell Chem. Bio. 2016, 23, 1407.

6. Schumann, B.; Hahm, H.S.; …. Seeberger, P.H.; Science Transl. Med. 2017, 9, eaaf5347.

7. Kamena, F.; Tamborrini, M.; Liu, X.; Kwon, Y.-U.; Thompson, F.; Pluschke, G.; Seeberger; P.H.; Nature Chem. Bio., 2008, 4, 238.

8. Ghislieri, D.; Gilmore, K.; Seeberger, P.H.; Angew. Chem. Int. Ed. 2015, 54, 678-682.

9. Levesque, F.; Seeberger, P.H. Angew. Chem. Int. Ed. 2012, 51, 1706; Kopetzki, D.; Lévesque, F.; Seeberger, P.H.; Chem Eur. J. 2013, 19, 5450; Gilmore, K.; Seeberger, P.H.; Chem. Comm. 2014, 50, 12652.

10. Correia, C.A.; Gilmore, K.; McQuade, D.T.; Seeberger, P.H.; Angew. Chem. Int. Ed. 2015, 54, 4945.